Verrica Pharmaceuticals
Presence
Verrica Pharmaceuticals is a company listed under the stock ticker VRCA (US).
Executives
View the org chart displaying its 14 main executives
Most searched biographies at Verrica Pharmaceuticals
- Ted White, Director, President and Chief Executive Officer
- Lawrence Eichenfield, Director
- Sean Stalfort, Director
Create your alert
to follow the executive moves at Verrica Pharmaceuticals.
Pharmaceuticals
Verrica Pharmaceuticals has 1,865 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference - Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™ - Verrica Pharmaceuticals
- View more press releases Close
Social media about Verrica Pharmaceuticals
- Verrica Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Verrica Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Ted White 
Call Verrica Pharmaceuticals at +1 484...
